Biohaven (NYSE:BHVN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Biohaven (NYSE:BHVN) from a strong sell rating to a sell rating in a research report report published on Saturday.

BHVN has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Biohaven in a research report on Monday, December 29th. Royal Bank Of Canada increased their price objective on shares of Biohaven from $22.00 to $23.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. HC Wainwright cut their price objective on shares of Biohaven from $11.00 to $10.00 and set a “neutral” rating on the stock in a report on Wednesday, March 4th. Leerink Partners restated an “outperform” rating and issued a $15.00 price objective on shares of Biohaven in a report on Tuesday, March 3rd. Finally, William Blair restated a “market perform” rating on shares of Biohaven in a report on Friday, December 26th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Biohaven currently has a consensus rating of “Moderate Buy” and an average price target of $22.53.

Biohaven Price Performance

Shares of BHVN stock opened at $10.81 on Friday. Biohaven has a 1 year low of $7.48 and a 1 year high of $24.06. The firm’s 50 day moving average is $10.18 and its 200-day moving average is $11.41. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -1.55 and a beta of 1.34. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of 4.59.

Biohaven (NYSE:BHVN) last announced its earnings results on Monday, March 2nd. The company reported ($1.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.01. Sell-side analysts forecast that Biohaven will post -2.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Biohaven

Several large investors have recently bought and sold shares of the company. Emerald Mutual Fund Advisers Trust increased its stake in Biohaven by 0.4% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 173,656 shares of the company’s stock valued at $2,607,000 after purchasing an additional 657 shares in the last quarter. Sigma Planning Corp increased its stake in Biohaven by 9.2% in the fourth quarter. Sigma Planning Corp now owns 13,613 shares of the company’s stock valued at $154,000 after purchasing an additional 1,146 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Biohaven by 113.7% in the third quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock valued at $36,000 after purchasing an additional 1,268 shares in the last quarter. IFP Advisors Inc increased its stake in Biohaven by 55.4% in the fourth quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock valued at $46,000 after purchasing an additional 1,450 shares in the last quarter. Finally, Rafferty Asset Management LLC increased its stake in Biohaven by 1.3% in the second quarter. Rafferty Asset Management LLC now owns 121,189 shares of the company’s stock valued at $1,710,000 after purchasing an additional 1,503 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.